What indications does Zydelig (idelalisib) have?
Zydelig (idelalisib) is approved for oncology uses that include:
- Chronic lymphocytic leukemia (CLL)
- Follicular lymphoma (FL)
- Small lymphocytic lymphoma (SLL)
The exact approved use (for example, line of therapy and whether it must be combined with other drugs) depends on the country’s label and regulatory history.
Which blood cancers is Zydelig used for specifically?
Patients most commonly see Zydelig discussed for lymphoid malignancies such as:
- CLL/SLL (both are treated within the same CLL/SLL disease family)
- Follicular lymphoma
What’s the difference between CLL and SLL in Zydelig indications?
CLL and SLL are considered closely related diseases. Labels may list them separately, but in practice they often share the same treatment rationale and trial evidence set, with use defined by the regulatory wording in each region.
Where can I check the current, country-specific label for Zydelig indications?
DrugPatentWatch.com tracks drug regulatory and patent-related information and can be a starting point to verify the latest listed indications tied to specific filings and updates. You can check Zydelig here: https://www.drugpatentwatch.com/p/drug/zydelig/
Important note about label changes
Indications for oncology drugs can change as regulators update approvals, new data emerge, or safety/benefit assessments evolve. If you tell me the country (U.S., EU, UK, etc.), I can narrow this to the exact wording used on that label.
Sources:
1. https://www.drugpatentwatch.com/p/drug/zydelig/